Isolation of Three Strains of Type 1 Dengue Virus from a Local Outbreak of the Disease in Malaya

Smith, Chris

doi:10.1017/s0022172400044843

Cited by 21 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By 1800, A. aegypti had already become established in many large tropical cites around the world, especially in port cities in Asia and the New World. A. aegypti did not become the predominant Stegomyia species in many noncoastal cities until during and after the Second World War (Smith, 1956b).…”

Section: Evolution and Spread Of Dengue Virus Vectormentioning

confidence: 99%

Dengue Virus

Murugesan¹,

Mythreyee²

2020

Emerging and Reemerging Viral Pathogens

111

View full text Add to dashboard Cite

At some point in the past 2000À4000 years, DENVs moved out of the Asian jungle and into rural villages, where they were, and still are, transmitted to humans by peridomestic mosquitoes such as A. albopictus. Migration of people and commerce ultimately moved the viruses into larger villages, towns, and cities of tropical Asia, where the viruses were most likely transmitted sporadically by A. albopictus and possibly other closely related peridomestic Stegomyia species (Halstead, 2007). The slave trade and the resulting commerce were responsible for the introduction and the widespread distribution of an African mosquito, 284 16. DENGUE VIRUS EMERGING AND REEMERGING VIRAL PATHOGENS 288 16. DENGUE VIRUS EMERGING AND REEMERGING VIRAL PATHOGENS 292 16. DENGUE VIRUS EMERGING AND REEMERGING VIRAL PATHOGENS 294 16. DENGUE VIRUS EMERGING AND REEMERGING VIRAL PATHOGENS 296 16. DENGUE VIRUS EMERGING AND REEMERGING VIRAL PATHOGENS 298 16. DENGUE VIRUS EMERGING AND REEMERGING VIRAL PATHOGENS

show abstract

Section: Evolution and Spread Of Dengue Virus Vectormentioning

confidence: 99%

Dengue Virus

Murugesan¹,

Mythreyee²

2020

Emerging and Reemerging Viral Pathogens

111

View full text Add to dashboard Cite

show abstract

“…Clinically, it can be confused with influenza, rubella, malaria, chikungunya, leptospirosis or typhoid. The incubation period is four to seven days (range of [3][4][5][6][7][8][9][10][11][12][13][14]. The inoculation of the dengue virus to the human host starts with the bite of the infected female mosquito vector that introduces saliva containing the dengue virus into the bite site which then spreads to the possible target tissues such as lymph nodes, spleen, bone marrow and liver.…”

Section: Clinical Diseasementioning

confidence: 99%

“…Subsequently in the years 1904, 1932 and 1933, more reports were made of dengue outbreaks in various parts of Peninsular Malaysia, largely in ports and large cities (6). Dengue virus was first isolated in 1950 by Smith (7) and the first laboratory confirmation was carried out by the Institute of Medical Research in 1953. Since 1953, pockets of epidemics have occured in urban areas of Peninsular Malaysia.…”

Section: Introduction and Epidemiologymentioning

confidence: 99%

Dengue: Breakbone Fever, Hemorrhagia or Shock

Shamala¹

2008

JUMMEC

View full text Add to dashboard Cite

Dengue virus infection has been endemic in Malaysia and in the region for decades and the disease caused by the virus has led to increased morbidity and mortality each year. Dengue is now endemic in more than 110 countries worldwide with two-fifths of the world's population at risk. Dengue fever is a flu-like illness and clinical features vary with the age of the patient. Dengue haemorrhagic fever on the other hand, is characterized by high fever, haemorrhagic phenomena and in severe cases, circulatory failure. There is no specific treatment for dengue fever but careful clinical management frequently saves the lives of these patients. Vaccine development has been difficult as protection against one or two dengue viruses could actually increase the risk of more serious diseases. At present, the only method of preventing dengue is to combat the vector mosquitoes. Dengue is diagnosed by viral isolation and or serology. Current methods, some in-house and others commercial, are far from satisfactory. My laboratory has developed, evaluated and validated tests for dengue that now enable detection on the first day of illness in most cases. At the same time an important aspect of dengue prevention is protection. To this end, we have been investigating the various immune parameters such as T-cells, cytokines and antibody neutralizing activities to show that specific immune responses do occur in a selected Malaysian population which are HLA restricted, cytokine mediated and directed specifically at certain regions of the virus.

show abstract

“…In urban settings, DENV is found as four immunologically distinct types (serotypes), DENV1 to DENV4, which have approximately 30% divergence in their genomic nucleotide sequences (3)(4)(5)(6)(7). The disease may present with different degrees of manifestations that are classified by the WHO as dengue fever, dengue with warning signs, and severe dengue (8).…”

mentioning

confidence: 99%

Production of a Recombinant Dengue Virus 2 NS5 Protein and Potential Use as a Vaccine Antigen

Alves

Pereira

Fabris

et al. 2016

Clin Vaccine Immunol

View full text Add to dashboard Cite

Dengue fever is caused by any of the four known dengue virus serotypes (DENV1 to DENV4) that affect millions of people worldwide, causing a significant number of deaths. There are vaccines based on chimeric viruses, but they still are not in clinical use. Anti-DENV vaccine strategies based on nonstructural proteins are promising alternatives to those based on whole virus or structural proteins. The DENV nonstructural protein 5 (NS5) is the main target of anti-DENV T cell-based immune responses in humans. In this study, we purified a soluble recombinant form of DENV2 NS5 expressed in Escherichia coli at large amounts and high purity after optimization of expression conditions and purification steps. The purified DENV2 NS5 was recognized by serum from DENV1-, DENV2-, DENV3-, or DENV4-infected patients in an epitope-conformation-dependent manner. In addition, immunization of BALB/c mice with NS5 induced high levels of NS5-specific antibodies and expansion of gamma interferon-and tumor necrosis factor alpha-producing T cells. Moreover, mice immunized with purified NS5 were partially protected from lethal challenges with the DENV2 NGC strain and with a clinical isolate (JHA1). These results indicate that the recombinant NS5 protein preserves immunological determinants of the native protein and is a promising vaccine antigen capable of inducing protective immune responses. Dengue fever is an acute disease caused by dengue virus (DENV), an arbovirus belonging to the Flaviviridae family, transmitted by Aedes mosquitoes (1, 2). In urban settings, DENV is found as four immunologically distinct types (serotypes), DENV1 to DENV4, which have approximately 30% divergence in their genomic nucleotide sequences (3-7). The disease may present with different degrees of manifestations that are classified by the WHO as dengue fever, dengue with warning signs, and severe dengue (8). A recent study showed that, annually, an average of 96 million DENV-infected people develop symptoms with severity sufficient to change their routines (1); according to previous studies, about 500,000 cases develop into severe forms of disease, which may include hemorrhage and shock syndrome (9). The mortality rate in this group reaches 10% in hospitalized patients, increasing to 30% in nontreated DENV-infected patients (9-11). Despite the high epidemiological importance of dengue fever, no effective anti-DENV drug or vaccine formulation is in clinical use for treatment or prevention of the disease.Several strategies have been explored, aiming toward the development of an effective dengue vaccine (12-21). Nonetheless, a tetravalent vaccine formulation requires a neutralizing response to all four serotypes (22)(23)(24)(25). A poor vaccine-induced response to structural proteins of any of the four serotypes may pose a risk of the onset of antibody-dependent enhancement (ADE) of virus replication upon infection by a subneutralized serotype (22-25). Moreover, protection based on the induction of neutralizing antibodies targeting structural proteins may be neg...

show abstract

Isolation of Three Strains of Type 1 Dengue Virus from a Local Outbreak of the Disease in Malaya

Cited by 21 publications

References 15 publications

Dengue Virus

Dengue Virus

Dengue: Breakbone Fever, Hemorrhagia or Shock

Production of a Recombinant Dengue Virus 2 NS5 Protein and Potential Use as a Vaccine Antigen

Contact Info

Product

Resources

About